The Technical AnalystExchange: WSE Sector: Healthcare Industry: Biotechnology
Ryvu Therapeutics S.A. Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.45% PLN55.80
America/New_York / 17 mai 2024 @ 11:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 290.08 mill |
| EPS: | -4.00 |
| P/E: | -13.95 |
| Earnings Date: | May 15, 2024 |
| SharesOutstanding: | 23.12 mill |
| Avg Daily Volume: | 0.0040 mill |
| RATING 2024-05-17 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -13.95 | sector: PE 21.29 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.14x |
| Company: PE -13.95 | industry: PE 12.24 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
PLN-53.07 (-195.10%) PLN-108.87 |
| Date: 2024-05-19 |
| Expected Trading Range (DAY) |
|---|
|
PLN 54.56 - 57.04 ( +/- 2.22%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | PLN55.80 (1.45% ) |
| Volume | 0.0159 mill |
| Avg. Vol. | 0.0040 mill |
| % of Avg. Vol | 399.32 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RVU.WA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
RVU.WA
Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.